|
Telomir Pharmaceuticals, Inc, a leader in age-reversal science, announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines.
The findings include improved mitochondrial activity, reduced oxidative stress, restored calcium balance, and protection from toxic metal effects-offering a mechanistic foundation for the company's new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD).
The in vitro studies, conducted in collaboration with SmartAssays, demonstrated Telomir-1's ability to:
Improve cell viability under stress, particularly in dividing cell populations. Maintaining cell survival is critical for tissue repair, immune defense, and slowing the progression of degenerative conditions. Boost mitochondrial function, indicating stronger energy production. Healthy mitochondria are essential for powering cells and preventing energy loss that drives aging and diseases like Alzheimer's, Parkinson's, and autism.
Reduce reactive oxygen species (ROS), limiting oxidative damage. Excess ROS contributes to DNA damage, inflammation, neurodegeneration and cell death, all of which accelerate aging and chronic diseases.
Restore calcium signaling, helping maintain healthy cellular functions and communication.
Disrupted calcium balance impairs brain, muscle, and heart function and is a known trigger of cellular death and neurodegeneration.
Protect cells from metal-induced toxicity, including iron and copper-both linked to ROS formation, calcium dysregulation and accelerated cellular aging and death. Iron and copper accumulation drive oxidative stress and mitochondrial failure.
"This is a strong demonstration of Telomir-1's ability to restore core cell functions under conditions that mimic aging and stress," said Erez Aminov, CEO of Telomir. "These biological improvements give us confidence to pursue exploratory models in autism and spasmodic dysphonia, where these same cellular disruptions are widely documented and involved in disease initiation or progression."
Scientific rationale for expanding into autism and spasmodic dysphonia:
The cellular mechanisms targeted by Telomir-1-oxidative stress, mitochondrial dysfunction, calcium imbalance, and metal-induced toxicity-have been demonstrated in proliferating cells and may be directly relevant to both autism and spasmodic dysphonia.
Autism spectrum disorder (ASD) affects 1 in 36 children in the United States. While current therapies focus on behavioral symptoms, there are no FDA-approved treatments that address the underlying cellular biology. Research has shown that individuals with ASD exhibit shortened telomeres, mitochondrial dysfunction, oligodendrocytes, myelination dysfunctions and elevated oxidative stress-biological disruptions Telomir-1 was specifically designed to target.
Spasmodic dysphonia is a rare neurological voice disorder affecting about 50,000 Americans. It causes involuntary spasms in the vocal cords and gained public awareness when Robert F. Kennedy Jr. disclosed his diagnosis. Spasmodic dysphonia is currently treated with repeated botulinum toxin injections, offering only temporary relief. While telomere shortening has not yet been directly studied in Spasmodic dysphonia, the condition is marked by oxidative stress, neuroinflammation, metal ion accumulation and neurodegeneration-factors known to accelerate telomere attrition and neurodegeneration in other related neurological diseases.
"What's compelling is that Telomir-1 isn't just addressing one pathway-it's restoring balance, particularly in dividing cells, across multiple core stress systems that overlap with what has been reported in autism and spasmodic dysphonia," said Dr. Angel, Chief Scientific Advisor. "That's the foundation for our next stage of research."
|